Nanoscope Therapeutics Appoints Damon Daulerio as Executive Director of Regulatory Affairs
Nanoscope Therapeutics has appointed industry veteran Damon Daulerio as the new Executive Director of Regulatory Affairs. Daulerio brings 30 years of pharmaceutical experience, including significant leadership roles at Insmed, Novartis, and Alcon, specializing in ophthalmology and rare diseases. The appointment comes at a critical juncture for Nanoscope as it manages global regulatory reviews for its lead candidate, MOGENRY® (sonpiretigene isteparvovec). The company's Biologics License Application (BLA) is currently under FDA review in the United States, while a Japan New Drug Application (JNDA) is undergoing priority review by the PMDA. Daulerio will oversee Nanoscope’s global regulatory strategy and lead interactions with health authorities including the FDA, EMA, and PMDA to support the potential approval and commercial launch of MOGENRY® for treating inherited retinal dystrophies.
Tickers: $ALC $INSM $MNTS $NVS
Topics: Biotechnology Executive Hire Ophthalmology Regulatory Affairs